A Research Study of How a New Medicine NNC0148-0287 C (Insulin 287) Works in the Body of People With Kidney Problems

NCT ID: NCT03723785

Last Updated: 2024-07-12

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 58 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-11-09
• Study Completion Date: 2019-09-06

Brief Summary

This study will be conducted to look at the effect of decreased kidney function when getting one dose of insulin 287 and to guide dosing recommendations in people who have altered kidney function. Insulin 287 works in the body for a long time (long-acting). It is taken once a day by injecting under the skin. The main target patient group for insulin 287 is people with type 2 diabetes. Participants will get just one injection. The study will last for up to 80 days. Participants will have 11 out-patient visits with the study doctor and one in-house visit of 3 days and 2 nights. Participants will have some assessments like several blood draws, electrocardiograms (ECGs), urine collections and capillary blood sugar tests. Participants cannot take part if they are hypersensitive to the study medicine, if they received any investigational product within 90 days before screening, or if they have certain diseases e.g. HIV or hepatitis or heart problems. Participants have to take photos if they experience any allergic reactions and send them to their study doctor. Participants' kidney function will be examined by a so called "Iohexol test".

Conditions

Diabetes Mellitus, Type 2

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Participants with normal renal function

Participants with normal renal function (glomerular filtration rate \[GFR\] of greater than or equal to 90 ml/min) will receive single dose of insulin 287 on Day 1.

Group Type: EXPERIMENTAL

Insulin icodec

Intervention Type: DRUG

Participants will receive single dose of Insulin 287 subcutaneously (under the skin) on Day 1

Participants with mildly decreased renal function

Participants with mildly decreased renal function (GFR of 60 to less than 90 ml/min) will receive single dose of insulin 287 on Day 1.

Group Type: EXPERIMENTAL

Insulin icodec

Intervention Type: DRUG

Participants will receive single dose of Insulin 287 subcutaneously (under the skin) on Day 1

Participants with moderately decreased renal function

Participants with moderately decreased renal function (GFR of 30 to less than 60 ml/min) will receive single dose of insulin 287 on Day 1.

Group Type: EXPERIMENTAL

Insulin icodec

Intervention Type: DRUG

Participants will receive single dose of Insulin 287 subcutaneously (under the skin) on Day 1

Participants with severely decreased renal function

Participants with severely decreased renal function (GFR of less than 30 not requiring dialysis) will receive single dose of insulin 287 on Day 1.

Group Type: EXPERIMENTAL

Insulin icodec

Intervention Type: DRUG

Participants will receive single dose of Insulin 287 subcutaneously (under the skin) on Day 1

Participants with end-stage renal disease

Participants with end-stage renal disease requiring haemodialysis will receive single dose of insulin 287 on Day 1.

Group Type: EXPERIMENTAL

Insulin icodec

Intervention Type: DRUG

Participants will receive single dose of Insulin 287 subcutaneously (under the skin) on Day 1

Interventions

Insulin icodec

Participants will receive single dose of Insulin 287 subcutaneously (under the skin) on Day 1

Intervention Type: DRUG

Other Intervention Names

Insulin 287

Eligibility Criteria

Inclusion Criteria

• Male or female, aged 18-75 years (both inclusive) at the time of signing informed consent.
• Body mass index between 18.5 and 32.0 kg/sqm (both inclusive).
• Meeting the pre-defined Glomerular Filtration Rate (GFR) values based on a measured GFR using an exogenous substance as tracer (renal group 1-4) or being in treatment with haemodialysis (renal group 5).

Exclusion Criteria

• Known or suspected hypersensitivity to trial product or related products.
• Impaired liver function defined as Alanine Aminotransferase (ALT) greater than or equal to 2.5 times or Bilirubin greater than 1.5 times upper limit of normal at screening.
• Drugs known to affect creatinine clearance including cephalosporin and aminoglycoside antibiotics, flucytosine, cisplatin, cimetidine and trimethoprim within 14 days or 5 half-lives prior to the day of dosing of IMP.
• Renal group 1 (healthy subjects) exclusively: Unwilling to avoid use of prescription medicinal products or non-prescription drugs, except routine use of vitamins, occasional use of paracetamol, topical medication and contraceptives, within 14 days prior to the day of dosing.
• Renal Group 2-5 (renal impairment) exclusively: 1) Any disorder, except for conditions associated with renal impairment in the groups of subjects with reduced renal function, which in the investigator's opinion might jeopardise subject's safety, evaluation of results, or compliance with the protocol. Subjects with heart failure of functional class III-IV according to New York Heart Association (NYHA), subjects with Chronic obstructive pulmonary disease (COPD) grade 4 according to Global Initiative on Obstructive Lung Disease (GOLD), subjects with asthma step 5 according to Global Initiative for Asthma (GINA), subjects diagnosed with diabetes, subjects with uncontrolled treated/untreated hypertension (systolic blood pressure greater than or equal to 180 mmHg and /or diastolic blood pressure greater than or equal to 100 mmHg assessed in supine position) and other co-morbidities in terminal stages or which are decompensated or unstable should not be included in the study. 2) Subject requiring haemodialysis treatment unable or unwilling to undergo haemodialysis scheduled according to the standard clinical regimen throughout the trial period.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Novo Nordisk A/S

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Clinical Reporting Anchor and Disclosure (1452)

Role: STUDY_DIRECTOR

Novo Nordisk A/S

Locations

Charité Research Organisation GmbH

Berlin, , Germany

Countries

Germany

References

Haahr H, Cieslarova B, Hingst JR, Jiang S, Kristensen NR, Kupcova V, Norgreen L, Wagner FH, Ignatenko S. The Effect of Various Degrees of Renal or Hepatic Impairment on the Pharmacokinetic Properties of Once-Weekly Insulin Icodec. Clin Pharmacokinet. 2024 Jun;63(6):819-830. doi: 10.1007/s40262-024-01375-2. Epub 2024 May 9.

Reference Type: RESULT

PMID: 38722461 (View on PubMed)

Other Identifiers

2017-004529-34

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

U1111-1204-8972

Identifier Type: OTHER

Identifier Source: secondary_id

NN1436-4226

Identifier Type: -

Identifier Source: org_study_id